DiaMedica Therapeutics Inc. (DMAC)
Develops experimental drugs to treat stroke, preeclampsia, and inflammatory diseases.
$6.64-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+61.2%
The outlook
DMAC is trading near the middle of its 52-week range with mixed momentum against its moving averages. Analyst coverage shows an average price target roughly double the current price, though that represents a wide gap between current valuation and consensus expectations. Overall sentiment leans neutral.
What’s behind the score
Price trendMixed vs its moving averages
52-week range41% of the way from its 52-week low to high
Price targetAvg target +133% vs current price
Analyst price target
~12-month · 4 analysts$15.50average target+133.4% vs now
Now $6.64
Low $11.00High $25.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$357.8M
52-wk high
$10.42
52-wk low
$4.01
50-day avg
$6.46
200-day avg
$7.20
Trailing P/E
—